NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 237 filers reported holding NEKTAR THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $30,560 | -45.9% | 51,311 | -47.7% | 0.00% | 0.0% |
Q2 2023 | $56,443 | -72.1% | 98,129 | +557.8% | 0.00% | -87.5% |
Q4 2021 | $202,000 | -24.1% | 14,917 | +0.6% | 0.01% | -38.5% |
Q3 2021 | $266,000 | +12.2% | 14,832 | +7.3% | 0.01% | +18.2% |
Q2 2021 | $237,000 | -30.7% | 13,820 | -19.2% | 0.01% | -31.2% |
Q1 2021 | $342,000 | +66.0% | 17,103 | +41.3% | 0.02% | +45.5% |
Q4 2020 | $206,000 | -5.9% | 12,100 | +487.1% | 0.01% | -63.3% |
Q1 2018 | $219,000 | – | 2,061 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |